Mayne Pharma Group Ltd.ASX: MYX

MYX signs licence agreement for Blissel in Australia

· Issued by Mayne Pharma Group Ltd. via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Mayne Pharma Group Ltd. has signed an exclusive licence agreement with Italfarmaco for Blissel in Australia, a menopause hormone therapy product. Blissel is an ultra-low-dose estriol vaginal gel aimed at treating vaginal atrophy in postmenopausal women, filling a gap in the Australian market. The agreement allows Mayne Pharma to register, market, and distribute Blissel in Australia, with Italfarmaco retaining ownership and manufacturing responsibilities. Mayne Pharma anticipates that Blissel will significantly contribute to its international sales in the coming years.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/myx-signs-licence-agreement-for-blissel-in-australia

Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call

Release

ASX Announcement MAYNE PHARMA SIGNS EXCLUSIVE LICENCE AGREEMENT FOR BLISSEL® IN AUSTRALIA Key Points • Mayne Pharma has signed an exclusive five-year licence agreement with Italfarmaco S.A for the Australian rights to Blissel®, a menopause hormone therapy (MHT) comprising an...

Mayne Pharma Group Ltd. on 6ix

Story so far

Earlier from Mayne Pharma

Later from Mayne Pharma

All Mayne Pharma news releases